久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Pharmas lauded for aiding global pandemic fight

By LIU ZHIHUA | CHINA DAILY | Updated: 2022-06-13 07:39
Share
Share - WeChat
A staff member of Sinovac works on the COVID-19 vaccine production line in Beijing, on July 8, 2021. [Photo/Xinhua]

Great progress

Liu Yong, founder and chairman of Jiangsu Recbio Technology, said, "The research and development (R&D), production and commercialization of the Chinese pharmaceutical industry have made remarkable progress in recent years thanks to a supportive regulatory environment.

"Policy measures that attract high-end overseas talent, or enable high-tech enterprises to expand financing, have also provided strong support for domestic pharmaceutical enterprises to grow."

Data from the China International Development Cooperation Agency show that the nation has provided more than 2 billion doses of COVID-19 vaccines to a total of 120 countries and international organizations. China has also transferred vaccine manufacturing technologies to more than 20 nations, resulting in an overseas annual vaccine production capacity of 1 billion doses.

Sinovac Biotech, which has been granted access licenses by more than 60 countries, international organizations and regions in total for its COVID-19 vaccine CoronaVac, has supplied more than 2.8 billion doses of it worldwide.

The company also plans to establish vaccine factories in at least 10 countries, including Egypt, South Africa, Chile and Indonesia, to strengthen international cooperation.

It is helping Egypt build a fully automated cold storage facility to accommodate 150 million doses of vaccines.

On completion, the facility will be the largest vaccine storage center in Africa, greatly improving cold chain storage on that continent.

Sinovac Biotech helped with construction of the BRICS Vaccine Research and Development Center's branch in China and is also cooperating with universities, research institutions and industries in BRICS nations (Brazil, Russia, India, China and South Africa) and other countries.

Gao Qiang, the company's chief operating officer, said, "In order to play a better role in the global pharmaceutical industry, Chinese enterprises must advance innovation-driven development and strengthen global cooperation."

Sinopharm Group, a State-owned pharmaceutical company that produces nearly 100 vaccine products and more than 200 bio-products, spent more than 20 billion yuan ($3 billion) on scientific research during the 13th Five-Year Plan period (2016-20).

The company, which is increasing investment for the R&D, is the only one worldwide to independently develop not only vaccines, but also test kits and treatments for the disease. It has produced four COVID-19 test kits, four antivirus therapies, and four titles for vaccines or potential vaccines.

In total, more than 119 countries, regions and international organizations have approved the use of COVID-19 vaccines made by Sinopharm's subsidiary CNBG, which has produced more than 3 billion doses of such vaccines at home and overseas.

Sinopharm chairman Liu Jingzhen said, "Having been approved for use in a large number of countries and regions, our COVID-19 vaccines are the most widely used in the world, and have the largest inoculation population, the best safety record and the most efficient production capacity.

"We are proud to have contributed to the global containment of the disease and to have increased the worldwide presence of pharmaceutical products developed in China."

Shi Lichen, founder of medical consulting company Beijing Dingchen Consultancy, also spoke highly of the contribution to global anti-pandemic efforts made by Chinese enterprises that manufacture medical devices, especially as the Omicron variant has increased demand for rapid and convenient tests.

"Thanks to their solid manufacturing capacity and impressive efficiency in organizing the development and production of these urgently needed products, Chinese producers have been making COVID-19 test kits on a large scale to meet demand at home and abroad," Shi said.

|<< Previous 1 2 3 4 Next   >>|

Related Stories

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 久色视频在线观看 | 久久久日韩精品国产成人 | 特级黄色毛片视频 | 国产一区二区久久久 | 国产丝袜美腿高跟白浆 | 美女张开腿给男人捅 | 亚洲性xo| 久久99这里只有精品国产 | 韩国a级毛片 | 中文字幕亚洲精品久久 | 国产一级爱 | 精品国产90后在线观看 | 六月丁香久久丫 | 一级特黄aaa大片 | 午夜在线观看cao | 一级网站在线观看 | 男人天堂网在线观看 | 日本在线网 | 男人的天堂在线观看入口 | 国产精品久久久久久搜索 | 一级做a爰性色毛片免费 | 欧美日产国产亚洲综合图区一 | 在线观看日韩 | 狠狠综合久久久久综合 | 国产盗摄精品一区二区三区 | 日产一区两区三区 | 成 人 a v黄 色 | 中文字幕有码在线播放 | 99热成人精品热久久66 | 久草综合在线视频 | 欧美色网在线 | 国产主播大尺度精品福利 | 国产亚洲精品久久久久久久网站 | 一机毛片| 欧美日一本| 成人a视频在线观看 | 免费91最新地址永久入口 | 在线观看va | 成年人在线观看视频网站 | 99精品国产在热久久 | 精品国产三级a∨在线观看 精品国产三级a在线观看 |